Online
|
|
BSE Announcements on Dr Reddys Labs
Posted by :
MMB MessengerDr Reddys Laboratories Ltd has informed BSE regarding a Press Release dated July 30, 2009 titled "Dr. Reddys launches Execare in India"...
NSE Announcements on Dr Reddys Labs
Posted by : MMB MessengerDr. ReddyS Laboratories Ltd. has informed the Exchange regarding the outcome of Annual General Meeting held on July 22, 2009. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). ...
BSE Announcements on Dr Reddys Labs
Posted by : MMB MessengerDr Reddys Laboratories Ltd has informed BSE that the 25th Annual General Meeting (AGM) of the Company was held on July 22, 2009....
Drreddy new trading range could be 760-900....
Posted by : marketmanThe q1 results are good.... the scrip may be in trading band of 760-900 till the q2 results.......
NSE Announcements on Dr Reddys Labs
Posted by : MMB MessengerDr. ReddyS Laboratories Ltd. has informed the Exchange regarding a press release dated July 21, 2009, titled "Dr. Reddys Q1 FY10 Results, Revenues at Rs.18,189 million, up by 21% EBITDA at Rs.4,364 million, up by 90%, PAT at Rs.2,445 million, up by 120%". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). ...
NSE Announcements on Dr Reddys Labs
Posted by : MMB MessengerDr. Reddys Laboratories Ltd. has informed the Exchange regarding the standalone Results for the quarter ended on 30-JUN-2009 as follows: Net Sales of Rs. 114417 lacs for quarter ending on 30-JUN-2009 against Rs. 107925 lacs for the quarter ending on 30-JUN-2008. Net Profit / (Loss) of Rs. 22744 lacs for the quarter ending on 30-JUN-2009 against Rs. 21005 lacs for the quarter ending on 30-JUN-2008....
NSE Announcements on Dr Reddys Labs
Posted by : MMB MessengerDr. Reddys Laboratories Ltd. has informed the Exchange regarding the consolidated Results for the quarter ended on 30-JUN-2009 as follows: Net Sales of Rs. 177878 lacs for quarter ending on 30-JUN-2009 against Rs. 148126 lacs for the quarter ending on 30-JUN-2008. Net Profit / (Loss) of Rs. 23889 lacs for the quarter ending on 30-JUN-2009 against Rs. 9197 lacs for the quarter ending on 30-JUN-2008....
BSE Announcements on Dr Reddys Labs
Posted by : MMB MessengerDr Reddys Laboratories Ltd has informed BSE regarding a Press Release dated July 21, 2009 titled "Dr. Reddys Q1 FY10 Results"....
BSE Announcements on Dr Reddys Labs
Posted by : MMB Messenger
Dr Reddys Laboratories Ltd has announced the following Unaudited results for the quarter ended June 30, 2009:
The Company has posted a net profit of Rs 2274.40 million for the quarter ended June 30, 2009 as compared to Rs 2100.50 million for the quarter ended June 30, 2008. Total Income has increased from Rs 11185.30 million for the quarter ended June 30, 2008 to Rs 12207.10 million for the quarter ended June 30, 2009.
The Consolidated Results are as follows
The Group has posted a net profit attributable to the shareholders of the parent of Rs 2388.90 million for the quarter ended June 30, 2009 as compared to Rs 919.70 million for the quarter ended June 30, 2008. Total Income has increased from Rs 15476.10 million for the quarter ended June 30, 2008 to Rs 18393.50 million for the quarter ended June 30, 2009....
Road Ahead
Posted by : BAZEEGAR
The Indian domestic pharma-ceutical market size is esti-mated at US$10.76bn in the year 2008 and is expected to grow at a high CAGR of 9.9% percent till 2010 and thereafter at a CAGR of 9.5% till 2015.
With a number of countries in recession and drugs becoming almost a ne-cessity and Indian drug companies being generic manufacturers, export growth is unlikely to fall. Domestic growth is expected to remain healthy especially with the Government expected to open more Jan Aushadhis (a new low-priced medicine store chain). The outbreak of swine flu is also expected to aid the sales growth of Indian drug companies. Further, this in-dustry has witnessed a tremendous growth in consumer spending on health-care and is expected to continue the same. There is no doubt about the ca-pacity of Indian pharmaceutical sector in taking the big leap forward. Ac-cording to Ministry of Commerce & Industry the Indian domestic pharma-ceutical market size is estimated at US$10.76bn in the year 2008 and is ex-pected to grow at a high CAGR of 9.9% percent till 2010 and thereafter at a CAGR of 9.5% till 2015. Therefore, with the rise in disposable income, tremendous growth in exports, edge in CRAMS, stunning interest of global investors in Indian pharma and large number of USFDA approvals, Indian pharmaceuticals industry’s growth is vast and is expected to materialize soon.
Therefore, looking at the current scenario and future growth potential we expect PHARMA SECTOR to outperform the markets in medium term (i.e., 2-3 year) thereby providing excellent investment opportunities in the sector....
Opportunities
Posted by : BAZEEGAR
• Significant export potential
• Marketing alliances with MNCs to sell their products in domestic market
• Opening up off the health insurance sector
• Potential for developing India as a centre for international clinical trials. Niche player in global pharmaceutical R&D....
Weakness
Posted by : BAZEEGAR
• Highly fragmented industry
• Low investments in innovative R&D
• High Price Regulation
• Production of spurious and low quality drugs
• Strong linkages between industry and academia is lacking
• Lack of competency with MNCs for New Drug Discovery, Re-search and commercialization...
Strengths
Posted by : BAZEEGAR
• Cost Competitiveness
• Well developed industry with strong manufacturing base
• Third largest English speaking scientific and technical manpower in the world
• Strong marketing and distribution network...
Tremendous Exports
Posted by : BAZEEGAR
At present, India is among the top 20 pharmaceutical export-ers world-wide and with the largest number of US FDA inspected plants (119 plants), outside the USA.
The Indian pharmaceutical sector is emerging as one of the major contribu-tors to Indian exports with export earnings rising from a negligible amount in early 1990s to Rs.29,139.57 crores (US$7.24bn) by 2007-08. The exports of Drugs, pharmaceuticals & fine chemicals of India have grown at a com-pounded annual growth rate (CAGR) of 17.8% during the five-year period 2003-04 to 2007-08.
As per CMIE exports continued their upward trajectory growing by 36.7 percent in February 2009 to Rs.3,269.3 crore party aided by the deprecia-tion of the Indian rupee. Exports to US, India’s largest export destination, grew by a robust 69.8 percent in February 2009 to Rs.701.6 crore after de-clining by 1.5 per cent in January 2009. Further, with the outbreak of swine flu, companies like Cipla has received proposals from countries in Latin America, Mexico and Israel for the supply of the generic version of Roche’s branded anti-viral drug Tamiflu, which seems to be effective in treating the disease. Thus, Indian exports are expected to witness sharp rise in coming feture.
...
